Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a sterile solution for injection for intravenous use. It is used to assess myocardial perfusion and viability in patients undergoing cardiac imaging.

GNH USA supplies Myoview as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Myoview is employed in cardiac imaging to evaluate myocardial blood flow and detect coronary artery disease.

Myocardial perfusion imaging (stress and rest): provides quantitative assessment of myocardial perfusion during stress and rest conditions. Coronary artery disease detection: helps identify obstructive coronary lesions by highlighting perfusion defects. Myocardial viability assessment: distinguishes viable myocardium from scar tissue to guide revascularisation decisions.

Adverse reactions may occur following intravenous administration of Myoview.

Common Side Effects: - Nausea or vomiting - Transient flushing or warmth sensation - Headache or dizziness - Mild hypotension - Injection site pain or erythema

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Marked hypotension or cardiovascular collapse - Life‑threatening arrhythmias - Respiratory distress or bronchospasm - Severe chest pain indicative of myocardial ischemia

Myoview should be used with appropriate clinical assessment and adherence to radiation safety guidelines.

Patient assessment: evaluate cardiac stability and ability to tolerate SPECT imaging. Hypersensitivity: avoid in individuals with known allergy to tetrofosmin or formulation excipients. Pregnancy and lactation: use only if diagnostic benefit outweighs potential fetal or infant radiation risk. Renal or hepatic impairment: consider altered tracer clearance and adjust imaging protocol if needed. Concurrent cardiac drugs: be aware that vasodilators or beta‑blockers may affect myocardial uptake. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Tetrofosmin may interact with other agents that influence myocardial blood flow or radiotracer distribution.

Major Interactions (Avoid): - Concurrent administration of other myocardial perfusion radiopharmaceuticals (e.g., technetium‑99m sestamibi) within the same imaging session. - High‑dose vasodilators that markedly alter coronary flow during the uptake phase.

Moderate Interactions (Monitor Closely): - Beta‑blockers or calcium channel blockers that modify heart rate and perfusion patterns. - Drugs affecting thyroid function, as they may influence radiotracer kinetics. - Contrast agents used in CT that could interfere with subsequent SPECT imaging.